Medical Policy: 02.04.37
Original Effective Date: October 2012
Reviewed: June 2016
Revised: June 2016
Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions may apply. Benefits may vary based on contract, and individual member benefits must be verified. Wellmark determines medical necessity only if the benefit exists and no contract exclusions are applicable. This medical policy may not apply to FEP. Benefits are determined by the Federal Employee Program.
This Medical Policy document describes the status of medical technology at the time the document was developed. Since that time, new technology may have emerged or new medical literature may have been published. This Medical Policy will be reviewed regularly and be updated as scientific and medical literature becomes available.
There are currently genetic tests available for multiple cardiac conditions. This includes various channelopathies and other systemic conditions effecting cardiac health.
Currently, interpretation of cardiac ion channelopathy mutation testing is complicated by several factors. The pathophysiologic significance of each of the discrete mutations is an important part of the interpretation of genetic analysis. Laboratories that test for cardiac ion channelopathies keep a database of known pathologic mutations; however, these are mainly proprietary and may vary among different laboratories. In addition, the probability that a specific mutation is pathophysiologically significant is greatly increased if the same mutation has been reported in other cases. However, a mutation may also be found that has not definitely been associated with a disorder and therefore may or may not be pathologic.
As the prevalence of genetic testing has increased, the limitations become more important to the practicing physician. Testing may reveal a change in the patient’s genome from the typical sequence, but certifying a mutation as the clinical cause of a patient’s disease remains a challenge.
The expression levels of various genes in circulating white blood cell or whole blood samples have been reported to discriminate between cases of obstructive coronary artery disease (CAD) and healthy controls. Multiplex gene expression testing can be combined with other risk factors to predict the likelihood of obstructive CAD in patients who present with chest pain or other suggestive symptoms, or in asymptomatic patients who are at high risk of CAD.
Heart disease is the leading cause of mortality in the U.S. and, together with cerebrovascular disease, accounted for 31% of deaths in 2007. Individuals with signs and symptoms of obstructive coronary artery disease (CAD), the result of a chronic inflammatory process that ultimately results in progressive luminal narrowing and acute coronary syndromes, may be evaluated with a variety of tests according to prior risk. Coronary angiography is the gold standard for diagnosing obstructive CAD, but it is invasive and associated with a low but finite risk of harm. Thus, coronary angiography is recommended for patients at a high prior risk of CAD according to history, physical findings, electrocardiogram, and biomarkers of cardiac injury. For patients initially assessed at low-to-intermediate risk, observation and noninvasive diagnostic methods, which may include imaging methods such as coronary computed tomographic angiography, may be recommended. Nevertheless, even noninvasive imaging methods have potential risks of exposure to radiation and contrast material. In addition, coronary angiography has a relatively low yield despite risk stratification recommendations. In one study of nearly 400,000 patients without known CAD undergoing elective coronary angiography, approximately 38% were positive for obstructive CAD (using the CAD definition, stenosis of 50% or more of the diameter of the left main coronary artery or stenosis of 70% or more of the diameter of a major epicardial or branch vessel that was more than 2.0 mm in diameter; result was 41% if using the broader definition, stenosis of 50% or more in any coronary vessel). Thus, methods of improving patient risk prediction prior to diagnostic testing are needed.
A CAD classifier has been developed based on the expression levels, in whole blood samples, of 23 genes plus patient age and sex. This information is combined in an algorithm to produce a score from 1 to 40, with higher values associated with a higher likelihood of obstructive CAD. The test is marketed as Corus CAD™ (CardioDx, Inc.). The intended population is stable, nondiabetic patients suspected of CAD either because of symptoms, a high-risk history, or a recent positive or inconclusive test result by conventional methods.
The Corus CAD™ test is not a manufactured test kit and has not been reviewed by the U.S. Food and Drug Administration (FDA). Rather, it is a laboratory-developed test (LDT), offered by the Clinical Laboratory Improvement Act (CLIA)-licensed CardioDx Commercial Laboratory.
Brugada Syndrome is characterized by cardiac conduction abnormalities which increase the risk of syncope, ventricular arrhythmia, and sudden cardiac death. Inheritance occurs in an autosomal dominant manner with patients typically having an affected parent. Children of affected parents have a 50% chance of inheriting the mutation. The instance of de novo mutations is very low and is estimated to be only 1% of cases.
The disorder primarily manifests during adulthood although ages between two days and 85 years have been reported. Geno typical males are more likely to be affected than geno typical females (approximately an 8:1 ratio). Brugada syndrome is estimated to be responsible for 12% of SCD cases For both genders there is an equally high risk of ventricular arrhythmias or sudden death. Penetrance is highly variable, with phenotypes ranging from asymptomatic expression to death within the first year of life. Management has focused on the use of implantable cardiac defibrillators (ICD) in patients with syncope or cardiac arrest and isoproterenol for electrical storms. Patients who are asymptomatic can be closely followed to determine if ICD implantation is necessary.
The diagnosis of Brugada Syndrome is considered definite when the characteristic EKG pattern is present with at least one of the following clinical features: documented ventricular arrhythmia, sudden cardiac death in a family member <45 years old, characteristic EKG pattern in a family member, inducible ventricular arrhythmias on EP studies, syncope, or nocturnal agonal respirations.
Congenital long QT syndrome (LQTS) is an inherited disorder characterized by the lengthening of the repolarization phase of the ventricular action potential, increasing the risk of arrhythmic events, such as torsades de pointes, which may in turn result in syncope and sudden cardiac death. Management has focused on the use of beta blockers as first-line treatment, with pacemakers or implantation cardioverter defibrillators (ICD) as second-line therapy.
Congenital LQTS usually manifests itself before the age of 40 years. Frequently, syncope or sudden death occurs during physical exertion or emotional excitement. LQTS may be considered when a long QT interval is incidentally observed on an ECG. Diagnostic criteria for LQTS have been established, which focus on ECG findings and clinical and family history (i.e., Schwartz criteria, see following table). The Schwartz criteria are commonly used as a diagnostic scoring system for LQTS. The most recent version of this scoring system is shown below. A score of 4 or greater indicates a high probability that LQTS is present; a score of 2 to 3, a moderate-to-high probability; and a score of 1 or less indicates a low probability of the disorder. Prior to the availability of genetic testing, it was not possible to test the sensitivity and specificity of this scoring system; and since there is still no perfect gold standard for diagnosing LQTS.
LQTS is a disorder that may lead to catastrophic outcomes, ie, sudden cardiac death in otherwise healthy individuals. Diagnosis using clinical methods alone may lead to underdiagnosis of LQTS, thus exposing undiagnosed patients to the risk of sudden cardiac arrest. For patients in whom the clinical diagnosis of LQTS is uncertain, genetic testing may be the only way to further clarify whether LQTS is present. Patients who are identified as genetic carriers of LQTS mutations have a non-negligible risk of adverse cardiac events even in the absence of clinical signs and symptoms of the disorder. Therefore, treatment is likely indicated for patients found to have a LQTS mutation, with or without other signs or symptoms.
There is not sufficient evidence to conclude that the information obtained from genetic testing on risk assessment leads to important changes in clinical management. Most patients will be treated with betablocker therapy and lifestyle modifications, and it has not been possible to identify a group with low enough risk to forego this conservative treatment. Conversely, for high-risk patients, there is no evidence suggesting that genetic testing influences the decision to insert an ICD and/or otherwise intensify treatment.
|History of torsades de pointes||2|
|Notched T-waves in three leads||1|
|Low heart rate for age||0.5|
|Syncope brought on by stress||2|
|Syncope without stress||1|
|Family members with definite LQTS||1|
|Unexplained sudden death in immediate family members younger than 30 years of age||0.5|
Short QT syndrome is a condition that can cause a disruption of the heart's normal rhythm (arrhythmia). In people with this condition, the heart (cardiac) muscle takes less time than usual to recharge between beats. The term "short QT" refers to a specific pattern of heart activity that is detected with an electrocardiogram (EKG), which is a test used to measure the electrical activity of the heart. In people with this condition, the part of the heartbeat known as the QT interval is abnormally short.
SQTS has been linked predominantly to mutations in 3 genes KCNH2, KCNJ2, and KCNQ1. Some individuals with SQTS do not have a mutation in these genes suggesting changes in other genes may also cause this disorder.
No studies were identified that provide evidence for the clinical utility of genetic testing for SQTS. Clinical sensitivity for the test is low with laboratory testing providers estimating a yield as low as 15%.
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a condition characterized by an abnormal heart rhythm (arrhythmia). As the heart rate increases in response to physical activity or emotional stress, it can trigger heartbeat called ventricular tachycardia.
Management of CPVT is primarily with beta-blockers. If protection is incomplete (ie, recurrence of syncope or arrhythmia), then flecainide may be added. If recurrence continues, an ICD may be necessary with optimized pharmacologic management continued postimplantation. Lifestyle modification with the avoidance of strenuous exercise is recommended for all CPVT patients.
Familial TAAD is believed to account for at least 20 percent of thoracic aortic aneurysms and dissections. In the remainder of cases, the abnormalities are thought to be caused by factors that are not inherited, such as damage to the walls of the aorta from aging, tobacco use, injury, or disease.
Ambry Genetics offers “TAADNEXT,” an NGS panel which simultaneously analyzes 20 genes that are associated with TAADs, MFS and related disorders. Published studies on the analytic validity of genetic testing for connective tissue disorders associated with thoracic aortic aneurysms are lacking. The sensitivity of sequence analysis for individual mutations for these disorders is generally high for certain disorders, but lower, for others. Conventional testing for these disorders has historically consisted of sequencing for individual mutations associated with one suspected disorder, followed by duplication/deletion analysis if sequencing is negative. More recently, panel testing by next-generation sequencing (NGS) tests has been developed to test for multiple syndromes simultaneously.
DCM is defined as the presence of left ventricular enlargement and dilatation in conjunction with significant systolic dysfunction. Dilated cardiomyopathy has an estimated prevalence of 1 in 2700 in the United States. The age of onset for DCM is variable, ranging from infancy to the eighth decade, with most individuals developing symptoms in the fourth through sixth decade. Primary clinical manifestations of DCM are heart failure and arrhythmias. Symptoms of heart failure, such as dyspnea on exertion and peripheral edema, are the most common presentation of DCM. These symptoms are generally gradual in onset and slowly progressive over time. Progressive myocardial dysfunction also may lead to electrical instability and arrhythmias. Symptoms of arrhythmias may include light-headedness, syncope or sudden cardiac arrest.
Many genetic mutations on more than 40 different genes have been associated with DCM. This remains an active area of research, and it is likely that many more mutations will be identified in the future. Analytic validity of genetic testing for DCM is expected to be high when testing is performed by direct sequencing or next-generation sequencing. In contrast, clinical validity is not high. The percentage of patients with idiopathic DCM who have a genetic mutation (clinical sensitivity) is relatively low.
Treatment of DCM is similar to that for other causes of heart failure. This includes medications to reduce fluid overload and relieve strain on the heart, and lifestyle modifications such as salt restriction. Patients with clinically significant arrhythmias also may be treated with antiarrhythmic medications, pacemaker implantation, and/or an automatic implantable cardiac defibrillator (AICD). AICD placement for primary prevention also may be performed if criteria for low ejection fraction and/or other clinical symptoms are present. End-stage DCM can be treated with cardiac transplantation.
Familial hypertrophic cardiomyopathy (HCM) is an inherited condition that is caused by a mutation in 1 or more of the cardiac sarcomere genes. HCM is associated with numerous cardiac abnormalities, the most serious of which is sudden cardiac death (SCD). Genetic testing for HCM-associated mutations is currently available through a number of commercial laboratories.
For individuals at risk for HCM (first-degree relatives), genetic testing is most useful when there is a known mutation in the family. In this situation, genetic testing will establish the presence or absence of the same mutation in a close relative with a high degree of certainty. Absence of this mutation will establish that the individual has not inherited the familial predisposition to HCM and thus has a similar risk of developing HCM as the general population. These patients no longer need ongoing surveillance for the presence of clinical signs of HCM. Therefore, genetic testing may be considered medically necessary for first-degree relatives of individuals with a known pathologic mutation.
For at-risk individuals without a known mutation in the family, the evidence does not permit conclusions of the effect of genetic testing on outcomes, since there is not a clear relationship between testing and improved outcomes. For at-risk individuals who have a family member with HCM who tests negative for pathologic mutations, genetic testing is not medically necessary.
|AmbryGeneticsa (Aliso Viejo, CA)||Yes||Yes||Yes||No|
|GeneDX (Gaithersburg, MD)||Yes||Yes||Yes||Yes|
|John Welsh Cardiovascular Diagnostic Laboratory,Baylor College of Medicineb (Houston, TX)||Yes||Yes||Yes||Yes|
|Prevention Genetics (Marshfield, WI)||No||Yes||No||No|
|Transgenomic/FAMILIONb (New Haven, CT)||Yes||Yes||Yes||Yes|
BrS: Brugada syndrome; CPVT: catecholaminergic polymorphic ventricular tachycardia; LQTS: long QT syndrome; SQTS: short QT syndrome.
The FAMILION test is currently performed exclusively at designated laboratory facilities provided by Transgenomics® Inc. (New Haven, CT) The FAMILION family of tests detects genetic mutations that can cause cardiac channelopathies, cardiomyopathies, and other cardiopathies. Cardiac channelopathies are rare, potentially lethal inherited heart conditions, including Long QT Syndrome (LQTS), Short QT Syndrome (SQTS), Brugada Syndrome (BrS) and Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). Cardiomyopathies are potentially lethal progressive diseases that affect the heart muscle including, Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Conduction Disease associated with DCM (CD-DCM), and Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC). Other cardiopathies include Marfan Syndrome and familial Thoracic Aortic Aneurysms and Aortic Dissections (Marfan/TAAD). According to information available online the test “may use some reagents produced for research purposes only."
HCM First, CM Next, DCM Next, RhythmNext, RhythmFirst, CPVTNext, ARVDNext, CardioNext are all multi-gene test panels performed by AmbryGeneticsa (Aliso Viejo, CA).
CardioNext is a next generation sequencing (NGS) and deletion/duplication panel of 84 genes associated with hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic right ventricular dysplasia (ARVD), left ventricular non-compaction (LVNC), restrictive cardiomyopathy, long QT syndrome (LQTS), Brugada syndrome (BrS), catecholaminergic polymorphic ventricular tachycardia (CPVT) and short QT syndrome. This panel also includes genes that cause cardiomyopathy that is associated with inherited muscular dystrophies, as well as some genes associated with congenital heart defects.
RhythmNext is a panel including 34 genes associated with arrhythmogenic right ventricular dysplasia (ARVD), Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT), long QT syndrome (LQTS), short QT syndrome (SQTS), other arrhythmias/channelopathies, as well as sudden cardiac arrest.
The Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA) jointly published an expert consensus statement on genetic testing for channelopathies and cardiomyopathies. This document made the following specific recommendations concerning testing for LQTS.
The Evaluation of Genomic Applications in Practice and Prevention Working Group (EWG) found insufficient evidence to recommend testing for the 9p21 genetic variant or 57 other variants in 28 genes to assess risk for cardiovascular disease (CVD) in the general population, specifically heart disease and stroke. The EWG found that the magnitude of net health benefit from use of any of these tests alone or in combination is negligible. The EWG discourages clinical use unless further evidence supports improved clinical outcomes. Based on the available evidence, the overall certainty of net health benefit is deemed “Low.”
The Canadian Cardiovascular Society and Canadian Hearth Rhythm Society published a joint position paper in 2011.24 Genetic testing was recommended for cardiac arrest survivors with LQTS for the purpose of familial screening as well as those with syncope with QTc prolongation as well as asymptomatic patients with QTc prolongation with a high clinical suspicion of LQTS. For clinically suspect CPVT, testing is recommended for the purpose of familial screening.
Gene expression testing to predict coronary artery disease is considered investigational.
Multi-gene next generation panels, (i.e. CardioNext, Familion, RhythmFirst) are not medically necessary. The medical necessity of testing is based on medical factors for individual conditions and not panels that test for multiple syndromes or cardiac conditions without clinical cause. Testing for the individual condition will be expected when medically necessary criteria is present.
Genetic testing for Brugada syndrome is considered investigational. The low clinical sensitivity of genetic testing for BrS limits its diagnostic capability.
Genetic testing for Short QT Syndrome is considered not medically necessary.
Genetic testing in patients with suspected CPTV may be considered medically necessary for the following indications:
Genetic testing in patients with suspected congenital long QT syndrome may be considered medically necessary for the following indications:
Individuals who do not meet the clinical criteria for LQTS (ie, those with a Schwartz score <4), but who have:
Genetic testing for LQTS to determine prognosis and/or direct therapy in patients with known LQTS is considered medically necessary only when needed to determine index case mutation.
Genetic testing for predisposition to LQTS is considered not medically necessary for patients with a family history of LQTS in which an index case has tested negative for mutations.
Genetic testing for predisposition to hypertrophic cardiomyopathy (HCM) may be considered medically necessary for individuals who are at risk for development of HCM:
Genetic testing for predisposition to HCM is considered not medically necessary for patients with a family history of HCM in which a first-degree relative has tested negative for pathologic mutations.
Genetic testing for determining the diagnosis and for management of all other hereditary cardiomyopathies, including but not limited to, arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C), dilated, restrictive, and left ventricular noncompaction cardiomyopathies, is considered not medically necessary for all indications.
Genetic testing for predisposition to HCM is considered not medically necessary for all other patient populations, including but not limited to individuals who have a first-degree relative with clinical HCM, but in whom genetic testing is unavailable.
Genetic testing for dilated cardiomyopathy is considered not medically necessary.
Clinical utility of genetic testing for DCM is uncertain. For a patient who is diagnosed with idiopathic DCM, the presence of a genetic mutation will not change treatment or prognosis. For an individual at risk due to genetic DCM in the family, genetic testing can identify whether the mutation has been inherited. However, it is uncertain how knowledge of a mutation will improve outcomes for an asymptomatic individual. Early treatment based on a genetic diagnosis is unproven. Uncertain accuracy of predictive testing makes it uncertain whether changes in management will improve outcomes.
Genetic testing for thoracic aortic aneurysms and dissections (TAAD) medically necessary for:
Genetic testing for atrial fibrillation is considered not medically necessary.
Panel testing is considered not medically necessary.
Clinical utility of gene expression assays has not been demonstrated. There hasn't been convincing evidence that the use of gene expression scores reduce unnecessary coronary angiography. There is insufficient evidence in the clinical literature demonstrating that these test have a role in clinical decision-making or have a beneficial effect on health outcomes. Further studies are needed to determine the analytic validity, clinical validity and clinical utility of these test. Diagnosis of Brugada syndrome is considered definitive with clinical symptoms and history. Testing only to determine hereditary implications to others family members is considered not a medical necessity, as there is no changes to the individuals plan of care or health outcomes. Testing for multiple conditions without clinical indications for testing has not been proven to change net health outcomes.
trial. J Cardiovasc Transl Res. 2012 Jun;5(3):366-74. Epub 2012 Mar 7. PubMed PMID: 22396313; PubMed Central PMCID: PMC3349850.
statement from the American Heart Association. Circulation. 2012 Jul 3;126(1):142-57. Epub 2012 May 29. PubMed PMID: 22645291.
Wellmark medical policies address the complex issue of technology assessment of new and emerging treatments, devices, drugs, etc. They are developed to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. Wellmark medical policies contain only a partial, general description of plan or program benefits and do not constitute a contract. Wellmark does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Wellmark or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. Our medical policies may be updated and therefore are subject to change without notice.
*Current Procedural Terminology © 2012 American Medical Association. All Rights Reserved.